EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interleukin‐1α‐Mediated Activation of TNF ‐α/ NF ‐ κB Signaling Confers Resistance to Osimertinib in EGFR ‐Mutant Non‐Small‐Cell Lung Cancer

Wira Winardi, Yoichiro Mitsuishi iD, Hironari Matsuda iD, Fumiyuki Takahashi, Daisuke Hayakawa, Koichiro Kanamori, Ikuko Nakamura, Aditya Wirawan, Moulid Hidayat iD, Adityo Wibowo iD, Takehito Shukuya iD, Ken Tajima und 3 weitere

Thoracic Cancer · 2026-07 · 17 (14)

DOI: 10.1111/1759-7714.70360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 17.07.2026. Verfasst von Wira Winardi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Acrylamides, Lung Neoplasms. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science (JSPS), Japan Society for the Promotion of Science London.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung cancer is the leading cause of cancer‐related deaths worldwide. Although osimertinib is more effective than previous‐generation drugs, its efficacy is often limited by both primary and acquired resistance. Cycling cancer persister cells (CPCs) have recently emerged as a transient, drug‐tolerant subpopulation that may contribute to early resistance to targeted therapies. However, their biological characteristics and role in osimertinib resistance remain poorly understood.

Methods

We established osimertinib‐resistant CPCs derived from epidermal growth factor receptor ( EGFR) ‐mutant non‐small‐cell lung cancer (NSCLC) cell lines PC9 and HCC827. RNA sequencing (RNA‐seq) was performed to identify CPC‐specific transcriptional programs.

Results

RNA‐seq analyses demonstrated that the tumor necrosis factor alpha (TNF‐α)/nuclear factor‐κB (NF‐κB) signaling pathway was upregulated in osimertinib‐resistant PC9 cells (PC9‐CPCs), with interleukin‐1 alpha (IL‐1α) being the most significantly overexpressed gene. Treatment with IL‐1α increased TNF‐α and NF‐κB p65 expression in PC9 parental cells, whereas IL‐1α inhibition decreased TNF‐α expression in PC9‐CPCs. Consequently, the inhibition of either IL‐1α or TNF‐α restored the sensitivity of EGFR ‐mutant NSCLC cells to osimertinib. Immunohistochemical analysis confirmed that NF‐κB expression was higher in tumor specimens from patients who had developed osimertinib resistance than in specimens collected before treatment.

Conclusion

CPCs exhibit a distinct inflammatory phenotype driven by IL‐1α–driven activation of the TNF‐α/NF‐κB axis, representing an alternative mechanism underlying osimertinib resistance. Targeting IL‐1α or TNF‐α may provide a promising strategy to overcome resistance in patients with EGFR ‐mutant NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAniline CompoundsAcrylamidesLung NeoplasmsTumor Necrosis Factor-alphaDrug Resistance, NeoplasmNF-kappa BInterleukin-1alphaHumansPyrimidinesIndolesErbB ReceptorsSignal TransductionAnimalsMutationMiceCell Line, Tumor

Stichwörter der Autor:innen

EGFR‐mutant non‐small‐cell lung cancercycling cancer persister cellsdrug resistanceosimertinib

Substanzen

osimertinibPyrimidinesAniline CompoundsAcrylamidesIndolesTumor Necrosis Factor-alphaErbB ReceptorsNF-kappa BEGFR protein, humanInterleukin-1alpha

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
  • Department of Human Pathology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
  • Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.

ORCID-Profile: Yoichiro Mitsuishi, Hironari Matsuda, Moulid Hidayat, Adityo Wibowo, Takehito Shukuya, Takuo Hayashi, Shinji Kohsaka, Kazuhisa Takahashi

Förderung

  • Japan Society for the Promotion of Science (JSPS)
  • Japan Society for the Promotion of Science London

Zitieren

APA

Winardi, W., Mitsuishi, Y., Matsuda, H., Takahashi, F., Hayakawa, D., Kanamori, K., Nakamura, I., Wirawan, A., Hidayat, M., Wibowo, A., Shukuya, T., Tajima, K., Hayashi, T., Kohsaka, S., & Takahashi, K. (2026). Interleukin‐1α‐Mediated Activation of TNF ‐α/ NF ‐ κB Signaling Confers Resistance to Osimertinib in EGFR ‐Mutant Non‐Small‐Cell Lung Cancer. Thoracic Cancer, 17(14). https://doi.org/10.1111/1759-7714.70360

Vancouver

Winardi W, Mitsuishi Y, Matsuda H, Takahashi F, Hayakawa D, Kanamori K, et al. Interleukin‐1α‐Mediated Activation of TNF ‐α/ NF ‐ κB Signaling Confers Resistance to Osimertinib in EGFR ‐Mutant Non‐Small‐Cell Lung Cancer. Thoracic Cancer. 2026;17(14). doi:10.1111/1759-7714.70360

BibTeX
@article{Winardi2026,
  author = {Winardi, Wira and Mitsuishi, Yoichiro and Matsuda, Hironari and Takahashi, Fumiyuki and Hayakawa, Daisuke and Kanamori, Koichiro and Nakamura, Ikuko and Wirawan, Aditya and Hidayat, Moulid and Wibowo, Adityo and Shukuya, Takehito and Tajima, Ken and Hayashi, Takuo and Kohsaka, Shinji and Takahashi, Kazuhisa},
  title = {Interleukin‐1α‐Mediated Activation of TNF ‐α/ NF ‐ κB Signaling Confers Resistance to Osimertinib in EGFR ‐Mutant Non‐Small‐Cell Lung Cancer},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {14},
  doi = {10.1111/1759-7714.70360}
}
Kostenlos starten →